multiplexed MAGEA1/PRAME TCR-T cell therapy / TSCan Therap - LARVOL DELTA

Multiplexed TCR-T cell therapy targeting MAGEA1 and PRAME enhances the activity of adoptive T cell therapy in pre-clinical models (SITC 2022) - "Notably, when treated with multiplexed MAGEA1/PRAME TCR-T, the mice achieved longer lasting tumor control compared to TCR-T targeting a single antigen. Conclusions These findings support the hypothesis that multiplexed TCR-T mimics the natural oligoclonal T-cell response to cancer and has the potential to overcome antigen heterogeneity, which may contribute to the observed lack of durability in monotherapy TCR-T clinical trials."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • HLA-A • MAGEA1 • PRAME

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) - "To address antigen heterogeneity, TScan developed a multiplexed TCR-T approach targeting two different cancer testis antigens via two different TCRs. One of these antigens, MAGE-A1, was identified by TScan’s discovery platform as the target of expanded tumor infiltrating T cells from a patient with head and neck cancer. The other antigen, PRAME, is highly expressed in a variety of cancers, including 90% of melanomas, 90% of head and neck cancers, and 50% of non-small cell lung cancers....In xenograft mouse models, each TCR was able to control the growth of tumors expressing their cognate antigen. To assess potential synergy, a mixture of two different cell lines expressing either MAGE-A1 or PRAME were grown as xenograft tumors in mice, mimicking the observed heterogeneity of these targets in human tumors. Notably, when treated with multiplexed MAGE-A1/PRAME TCR-T, the mice achieved longer lasting tumor control compared to either singleplexed treatment alone."

Preclinical • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Solid Tumor